{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.23","upperLimit":"4.1","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The length of time during and after the treatment of the cancer that a patient lives with the disease but it does not get worse. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"Full Range","groups":[{"description":"500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.","id":"OG000","title":"Dovitinib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From start of treatment until the date of death from any cause, assessed up to 100 months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}